IGC Pharma secures U.S. patent covering cannabinoid treatment for Tourette’s

IGC Pharma (IGC) announced that the United States Patent and Trademark Office has officially issued U.S. Patent No. 12,491,200, covering the Company’s novel microdose-based cannabinoid treatment of stuttering and Tourette’s Syndrome. The patent issuance follows the Notice of Allowance previously announced by the Company and now provides full intellectual property protection over a proprietary therapeutic approach that utilizes ultra-low doses of THC, alone or in combination with CBD or other agents, to modulate neural circuits involved in vocal disruptions, tics, and involuntary motor symptoms.